Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

LEVOFLOXACIN FOR SYSTEM SUITABILITY CRS (1.01 MG)

LEVOFLOXACIN FOR SYSTEM SUITABILITY CRS (1.01 MG)

138199-71-0

DISCOVER
REGORAFENIB MONOHYDRATE CRS (120 MG)

REGORAFENIB MONOHYDRATE CRS (120 MG)

1019206-88-2

DISCOVER
REGORAFENIB IMPURITY C CRS (10 MG)

REGORAFENIB IMPURITY C CRS (10 MG)

ND

DISCOVER
REGORAFENIB IMPURITY D CRS (10 MG)

REGORAFENIB IMPURITY D CRS (10 MG)

ND

DISCOVER
REGORAFENIB IMPURITY A CRS (15 MG)

REGORAFENIB IMPURITY A CRS (15 MG)

ND

DISCOVER
FLUPENTIXOL FOR SYSTEM SUITABILITY CRS (1.01 MG)

FLUPENTIXOL FOR SYSTEM SUITABILITY CRS (1.01 MG)

ND

DISCOVER
PRAZOSIN IMPURITY A CRS (0.002 MG)

PRAZOSIN IMPURITY A CRS (0.002 MG)

ND

DISCOVER
GINSENOSIDE RG1 CRS (15 MG)

GINSENOSIDE RG1 CRS (15 MG)

ND

DISCOVER
NILOTINIB HYDROCHLORIDE MONOHYDRATE CRS (100 MG)

NILOTINIB HYDROCHLORIDE MONOHYDRATE CRS (100 MG)

ND

DISCOVER
SORAFENIB CRS (10 MG)

SORAFENIB CRS (10 MG)

ND

DISCOVER
MOXIFLOXACIN FOR PEAK IDENTIFICATION A CRS (10 MG)

MOXIFLOXACIN FOR PEAK IDENTIFICATION A CRS (10 MG)

ND

DISCOVER
NILOTINIB FOR SYSTEM SUITABILITY CRS (15 MG)

NILOTINIB FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER